CNS Market Overview - neurology, pain and psychiatry

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2008-04-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.


Scope

  • An inter and intra-sector view of the CNS market and its key components neurology, pain, and psychiatry in Japan, the US, and 5EU
  • Market size, structure, key brands, and company prescription sales value and volume data analyzed in each sector
  • Top-line analysis of key indications in each sector, drawing on key insights with disease-specific market trends and forecasts
  • Assessment of the commercial viability of the future CNS market with strategic recommendations to aid R&D decisions


    • Report Highlights
    When comparing the three CNS sectors the pain sector is by far the largest by volume prescriptions, accounting for 53.5% of the 2007 CNS market total. However, in terms of value, psychiatry is the dominant sector, accounting for over 48% of total CNS sales, whereas neurology is the fastest growing sector.

    On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology.

    Currently dominated by Big Pharma players and a number of multi-blockbuster antidepressant and antipsychotic brands, the psychiatry market value will begin to decrease from 2010 onwards as key patents begin to expire. Nevertheless, continued investment will eventually see the R&D pipeline yield new improved agents with blockbuster potential.


    Reasons to Purchase

  • Identify the commercial and clinical characteristics for the major CNS markets across Japan, the US and M5EU
  • Understand the future market landscape to align R&D decisions and target the indications that offer the most opportunity to your company
  • Quantify the key historical company and brand dynamics that have shaped the three CNS market sectors

    • Table of Contents

    Other users found this report page using the following search terms: pain alzheimer psychiatry market cns neurology pain size psychiatry drugs drug top neurological

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.